Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
Form Type:
Zero Holdings:
Publication Time:
2014-11-13 06:21:20
Reporting Period:
Filing Date:
Accepted Time:
2014-11-13 06:21:20
SEC Url:
Form 4 Filing
Cik Name Symbol Sector (SIC) IRS No
1517022 Akebia Therapeutics Inc. AKBA Pharmaceutical Preparations (2834) 208756903
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1591467 P. John Butler C/o Akebia Therapeutics, Inc.
245 First Street, Suite 1100
Cambridge MA 02142
Ceo And President Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2014-11-11 30,500 $0.47 44,350 No 4 M Direct
Common Stock Acquisiton 2014-11-12 1,000 $10.31 45,350 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 P Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2014-11-11 30,500 $0.00 30,500 $0.47
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2023-09-16 No 4 M Direct
  1. The price reported in this Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $10.26 to $10.40, inclusive. The reporting person undertakes to provide Issuer, any security holder of Issuer, or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
  2. This transaction represents the acquisition of common stock as a result of the exercise and hold of derivative securities reported in Table II. This option was granted on September 16, 2013. Twenty-five percent vested on September 16, 2014 with the remaining seventy-five percent vesting in equal quarterly installments thereafter until fully vested on September 1, 2017.